Literature DB >> 6281679

A long-term follow-up study of 214 children with the syndrome of infantile spasms.

R Riikonen.   

Abstract

The long-term prognosis of 192 surviving children with the syndrome of infantile spasms was evaluated. The children had been admitted to three paediatric hospitals in Helsinki at the time of initial diagnosis. The aetiological factors of the syndrome were carefully studied in each case. ACTH therapy was employed in 162, usually for about six weeks. The follow-up study 3-19 (mean 10.4) years later was made at the Children's Hospital, University of Helsinki. The rate of mortality was 19.6 per cent. Normal development was seen in 12 per cent and slightly subnormal in 10.4 per cent of the surviving children. Psychiatric disorders were seen in 27.6 per cent of the survivors. Sensory defects were also common. Severe cerebral palsy was seen in 4 per cent. Other seizures after cessation of the infantile spasms were seen in 60 per cent. Serial EEG studies showed that the temporal lobe was the most common site of abnormality. Abnormalities in the temporal lobes were seen frequently in children with symptomatic neonatal hypoglycaemia as a probable cause of the spasms. Prognostically favourable factors were "idiopathic" aetiology, normal development and not other fits prior to the spasms, short treatment lag, good response to ACTH and short duration of the spasms. In this study early treatment seemed to be of great importance even with regard to mental development. The factors connected with a bad outcome were: symptomatic aetiology (especially brain malformations, early infections and tuberous sclerosis), slow development before spasms, other seizures before infantile spasms, early onset of the spasms, long treatment lag, long duration of the spasms and other later occurrence of myoclonic-astatic seizures (Lennox-Gastaut). Large doses of ACTH (120-160 units) were not associated with a better prognosis than the smaller doses (20-40 units). The benefit of long versus short treatment schedules could not be evaluated in this study. The relapse rate here was 32 per cent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281679     DOI: 10.1055/s-2008-1059590

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  40 in total

1.  Neuropathologic findings in surgically treated hemimegalencephaly: immunohistochemical, morphometric, and ultrastructural study.

Authors:  M J De Rosa; D L Secor; M Barsom; R S Fisher; H V Vinters
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Infantile spasms: the devil is in the details, but do we see the forest for the trees?

Authors:  Barbara C Jobst
Journal:  Epilepsy Curr       Date:  2011-09       Impact factor: 7.500

3.  Neonatal seizures due to hypoxic-ischemic encephalopathy: should we care?

Authors:  Eric Kossoff
Journal:  Epilepsy Curr       Date:  2011-09       Impact factor: 7.500

4.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

Review 5.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 6.  Treatment of Epileptic Encephalopathies: Current State of the Art.

Authors:  Hiroki Nariai; Susan Duberstein; Shlomo Shinnar
Journal:  J Child Neurol       Date:  2017-01-30       Impact factor: 1.987

Review 7.  Infantile spasms.

Authors:  R E Appleton
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

8.  A model of symptomatic infantile spasms syndrome.

Authors:  Morris H Scantlebury; Aristea S Galanopoulou; Lenka Chudomelova; Emmanuel Raffo; David Betancourth; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

9.  Endogenous methionine enkephalin may play an anticonvulsant role in the seizure-susceptible El mouse.

Authors:  S Koide; H Onishi; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

10.  Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.

Authors:  Kelly G Knupp; Erin Leister; Jason Coryell; Katherine C Nickels; Nicole Ryan; Elizabeth Juarez-Colunga; William D Gaillard; John R Mytinger; Anne T Berg; John Millichap; Douglas R Nordli; Sucheta Joshi; Renée A Shellhaas; Tobias Loddenkemper; Dennis Dlugos; Elaine Wirrell; Joseph Sullivan; Adam L Hartman; Eric H Kossoff; Zachary M Grinspan; Lorie Hamikawa
Journal:  Epilepsia       Date:  2016-09-12       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.